Randomized phase II study of maintenance pemetrexed, bevacizumab, and pemetrexed+bevacizumab after induction chemotherapy with carboplatin+pemetrexed in advanced nonsquamous NSCLC.
Not Applicable
Recruiting
- Conditions
- nonsquamous NSCLC
- Registration Number
- JPRN-UMIN000006620
- Lead Sponsor
- Kyoto Thoracic Oncology Research Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 99
Inclusion Criteria
Not provided
Exclusion Criteria
Induction chemotherapy 1.severe comorbit disease 2.history of hemoptysis, coagulation disorder and thrombosis 3.tumor cavitation 4.invasion to the major vessel 5.myocardial infarction or brain infarction within 6 months 6.pregnant or lactating woman 7.brain metastasis with high risk of bleeding 8.interstitial pneumonia 9.effusion needed drainage 10.surgery within 4 weeks 11.radiation within 4 weeks 12.drainage within 1 week 13.double cancer Maintenance chemotherapy 1)PD after induction chemotherapy 2)hemoptysis 3)bleeding tendency or thrombosis 4)ECOG PS 2-4
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1-year progression-free survival rate from randomization.
- Secondary Outcome Measures
Name Time Method